Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its Nasdaq debut on November 13, 2026, under the ticker symbol WWB, marking a significant milestone for the Shanghai-based immunology firm.
The company priced its initial public offering at $17.00 per share, but investor demand pushed the stock sharply higher on the first day of trading. Shares closed at $28.50, representing a gain of roughly 68 percent from the IPO price — a strong opening performance by any measure in the current biotech capital markets environment.
Read more Leverage Shares Launches 2x Long Anthropic ETF as ANT Debuts on Nasdaq →
Windward Bio operates in the immunology space, a therapeutic area that has drawn sustained investor interest as drugmakers pursue next-generation treatments for autoimmune and inflammatory conditions. The company's listing adds to a pipeline of biotech firms seeking U.S. public market access despite a volatile fundraising climate.
Qiming Venture Partners, one of Asia's prominent venture capital firms with a track record of backing life sciences companies, holds a portfolio stake in Windward Bio. The Nasdaq listing gives the company access to U.S. institutional capital to advance its clinical programs.
Continue reading at All Financial Services & Investing.